Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Thelin development (correction)

Executive Summary

Pfizer has commenced enrollment of patients in a Phase III study for Thelin (sitaxsentan) to support a U.S. filing for the treatment of pulmonary arterial hypertension. The "Sitaxentan Efficacy and Safety Trial With a Randomized Prospective Assessment of Adding Sildenafil" (SR-PAAS) is expected to be completed by June 2010. An article in "The Pink Sheet" inaccurately stated that Pfizer was likely to abandon a Thelin NDA (1"The Pink Sheet" Jan. 5, 2009, p. 8)

You may also be interested in...

FDA Not More Conservative Than EU, Jenkins Says; Investors Not Convinced

Perceptions that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown, Office of New Drugs Director John Jenkins said

Execs On The Move: Repro-Med Replaces Its CEO

At Repro-Med, James Beck has been replaced by Linda Tharby as CEO, and more.

Start-Up Spotlight: Pre Diagnostics Picks Up Momentum In Early Neurodegenerative Disease Detection

Norway’s Pre Diagnostics uses the intracellular approach to neurodegenerative disease diagnosis. It believes its technology will open up a world of precision medicine for Alzheimer’s disease patients.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts